LLY - Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict Boosting Stock Potential Says BofA Analyst | Benzinga
BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company (NYSE:LLY), with a price forecast of $1,000.
An advisory committee to the U.S. Food and Drug Administration (FDA) delivered a favorable verdict on the company’s Alzheimer’s treatment, donanemab, declaring its benefits to surpass the associated risks.
The outcome will support regulatory approval of donanemab in patients with mild cognitive impairment/mild dementia, Meacham writes.
Moreover, regarding tau stratification, the speakers stressed their support for donanemab’s effectiveness across tau subgroups, including the no/very low tau population that was excluded from the placebo-controlled trials given the ...